Phase 2 Trial: 25 of 36 Adverse-Risk AML Patients Respond to Two-Drug Regimen

3.8 · 7d ago · US · TECH

The Facts

  • Trial data published in Haematologica in September show 25 of 36 patients saw their cancer shrink or disappear during a 28-day course of treatment, and 19 of them entered complete remission. CBS News only
  • The trial tested whether two medications typically given to older AML patients would be effective for younger patients with adverse-risk disease; it was overseen by Dr. Justin Watts of Sylvester Comprehensive Cancer Center in Miami. CBS News only
  • Regimen: a pill taken daily for 28 days plus an infusion given daily during the first week of that period. CBS News only
  • About 44% of patients with adverse-risk AML see their cancer shrink or disappear with standard treatment. CBS News only
  • According to the trial data, enrolled patients spent less time in the hospital, needed fewer blood transfusions and had fewer infectious complications than those receiving standard treatment. CBS News only
Dive deeper · 4 more factsShow less
  • Over half of the trial patients went on to have bone marrow transplants. CBS News only
  • Patient Ryan Goepel, then 49, of Florida, was diagnosed with AML after blood tests in September 2024. He entered remission just over two weeks after starting the trial regimen and later underwent a transplant with a sister as a matching donor. CBS News only
  • The Cleveland Clinic puts the five-year survival rate for AML at about 30%. CBS News only
  • Dr. Mihir Shukla of NYU Langone, who was not involved in the study, said the results and another Phase 2 study are generating questions about changing the decades-long standard approach for these patients. CBS News only

Context

A Phase 2 clinical trial at Sylvester Comprehensive Cancer Center tested a two-drug regimen normally used in older patients on younger patients with adverse-risk acute myeloid leukemia, for whom standard chemotherapy is often ineffective.

Results published in Haematologica show 25 of 36 patients responded, with 19 reaching complete remission. One participant, Ryan Goepel, entered remission and later had a bone marrow transplant. An outside hematologist said the findings suggest certain populations may benefit, but the trial was small and early-phase.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 1.

4 Global Affairs Analyst This is a single-site Phase 2 trial with 36 patients published in a journal, a promising clinical result that could eventually influence AML treatment, but it has limited immediate impact and only one independent source.
4 News Editor A single-institution Phase 2 trial with 36 patients and a single independent source reports encouraging results for a niche patient group, which is meaningful to medicine but of limited immediate impact on the general public.
4 Science & Tech Analyst A single-institution Phase 2 trial with a small sample (36 patients) published in a peer-reviewed journal is a meaningful clinical advance for a hard-to-treat leukemia, but it is preliminary, has limited immediate impact on patients, and rests on one independent source.
4 Policy Expert This is a single-site Phase 2 trial publication with promising results but no regulatory approval or enacted policy, so its impact is limited to clinical research and a small patient population for now.
4 Informed Citizen This is a single-site Phase 2 trial with one independent source reporting promising but preliminary results for a niche patient population, so it has limited immediate impact on ordinary people despite its medical significance.
3 Business Analyst This is a small Phase 2 single-trial clinical result with 36 patients and one independent source, offering promising but preliminary medical news with limited immediate broad impact, though it could matter to AML patients and the field.
3 Critical Reader This is a single-site Phase 2 trial with 36 patients, published results that are early-stage and not yet changing standard care, so its impact is limited to a niche oncology population despite the promising response rate.

Source

← All stories